Andrew Weinberg

Company: AgonOx

Job title: President and CSO

Seminars:

Enhancing TIL Selection to Improve Specificity & Functionality 1:30 pm

Enriching highly tumor-reactive CD8+ TILs by selecting CD39/ CD103 double-positive cells Expanding exhausted TILs into billions while retaining tumorkilling functionality Demonstrating long-term persistence, trafficking, and efficacy in IL-2-supported clinical modelsRead more

day: Conference Day Two PM